newsfilter
← Latest News
Business Wire·

VBI Vaccines and Agenus Announce Collaboration to Evaluate VBI-1901 in Combination with Anti-PD-1 Balstilimab in a Phase 2 Study in Primary Glioblastoma Patients

- Randomized, controlled evaluation as part of INSIGhT adaptive platform trial expected to initiate around year-end 2022 - Study expected to assess VBI-1901 with concurrent balstilimab (anti-PD-1) administration in